drugset / Trial / NCT04522180
A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to determine the safety, tolerability, and efficacy of IONIS-GHR-LRx subcutaneous (SC) injection as monotherapy in patients with acromegaly.
Timeline
- Start
- 2021-01-04
- Primary completion
- 2022-07-15
- Completion
- 2023-05-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GHR-LRX | Antisense oligonucleotide | 120 mg | Subcutaneous |
| Subject | GHR-LRX | Antisense oligonucleotide | 160 mg | Subcutaneous |